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INTRODUCTION
Central serous chorioretinopathy (CSC) is characterized 
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Abstract
Purpose: To report the outcomes of half‑dose photodynamic therapy (PDT) in patients with chronic central 
serous chorioretinopathy (CSC).
Methods: A chart review of patients with chronic CSC who had received half‑dose verteporfin PDT (3 mg/m2) 
was performed. The main outcome measures were resolution of subretinal fluid and best corrected visual 
acuity (BCVA).
Results: Fifty‑three eyes of 51 patients with mean age of 45.01 ± 8.9 years were studied. Three, 6 and 
12 months after half‑dose PDT, subretinal fluid was completely resolved in 51 eyes (96.2%). In 2 eyes (one 
patient), subretinal fluid decreased at 3 months but one year later, an increase in subretinal fluid was 
detected on optical coherence tomography (OCT) which completely resolved following additional PDT. 
Another patient with recurrence of subretinal fluid rejected further treatment. Mean baseline central subfield 
thickness was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm after 3, 6 
and 12 months, respectively (all P‑values < 0.001). Mean BCVA was 0.33 ± 0.27 LogMAR before PDT and 
0.11 ± 0.18, 0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR, 3, 6 and 12 months and at final visit (up to 60 
months) after PDT, respectively (all P‑values < 0.001). Improvement ≥2 lines in BCVA occurred in 20 eyes 
(37.7%). Statistically significant correlations were found between improvement in BCVA and baseline BCVA, 
baseline central subfield thickness and central subfield thickness after resorption of subretinal fluid (P < 
0.001, P = 0.04 and P = 0.01, respectively). No complications attributed to PDT were observed.
Conclusion: Half‑dose PDT is effective for treatment of patients with chronic CSC.
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by serous neurosensory retinal detachment and/or 
retinal pigment epithelial detachment (PED) at the 
posterior pole.[1] Typically, acute CSC is a self‑limited 
process which spontaneously resolves within 
1‑4 months.[1] Accordingly, the current recommendation 
for management of acute CSC is observation and 
modification of risk factors.[2,3] Treatment is reserved for 
patients with fluid persisting more than 3 months, or 
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signs of chronicity including pigmentary changes and 
cystoid macular edema (CME).[1]
Conventionally, application of thermal laser 
photocoagulation for focal extrafoveal leakage has 
been shown to result in resolution of CSC.[1‑3] In recent 
years, photodynamic therapy (PDT) has been reported 
to enhance the absorption of subretinal fluid by reducing 
choroidal vascular hyperpermeability.[1‑3] Considering 
potential complications of conventional PDT including 
RPE atrophy, retinal pigment epithelium (RPE) rip 
and choroidal ischemia, a reduction in PDT fluence, 
verteporfin dose, or a decrease in both parameters has 
been suggested.[3]
Several studies, mostly small series, have reported 
promising results for half‑dose PDT in CSC.[4‑12] However, 
further evidence is required to establish the safety and 
efficacy of this protocol.[1] The aim of the present study is 
to report the outcomes of half‑dose PDT in a large series 
of patients with chronic CSC.
METHODS
In this retrospective study, medical records of all patients 
who had undergone PDT for chronic CSC from January 
2010 to April 2014 were reviewed. The Ethics Committee 
of Eye Research Center, Iran University of Medical 
Sciences, Tehran, Iran approved the study and informed 
consent for PDT had been obtained from the patients.
Inclusion criteria were persistent subretinal fluid for 
more than 3 months, or symptoms of less than 3 months’ 
duration associated with signs of chronicity such as 
RPE abnormalities or CME. Patients with confirmed or 
suspected chorioretinal disorders other than CSC which 
can produce subretinal exudation, such as choroidal 
neovascularization, polypoidal choroidal vasculopathy, 
or inflammatory retinal detachment, were excluded. 
Moreover, patients who received intravitreal injection of 
anti‑vascular endothelial growth factor (VEGF) agents or 
underwent laser photocoagulation during the previous 
6 months were excluded. At the time of treatment, no 
patient was on any medication known to affect CSC.
Main outcome measures were resolution of subretinal 
fluid and best corrected visual acuity (BCVA) which 
was measured at baseline, and 3, 6 and 12 months 
after PDT and at the last examination using a Snellen 
chart and converted to logarithm of minimum angle of 
resolution (LogMAR) notations for statistical analysis. 
Evaluation of macular detachment was performed 
using a spectral domain optical coherence tomography 
(SD‑OCT) machine (Spectralis, Heidelberg Engineering, 
Heidelberg, Germany) at each visit. At baseline, 
combined fluorescein angiography (FA) and indocyanine 
green angiography (ICGA) was performed in all patients.
PDT was performed by one of the two authors 
(MN and KGF) by administering half the normal dose 
(3 mg/m2) of verteporfin (Visudyne; Novartis AG, Basel, 
Switzerland). Verteporfin was infused over 8 minutes 
followed by 83 seconds delivery of laser energy at 
693 nm 10 minutes after initiating the infusion. Areas 
of choroidal hyperpermeability at the posterior pole on 
ICGA were treated.
Statistical analysis were performed using SPSS 
software version 15 (SPSS Inc. Chicago, IL, USA), and 
paired t‑test and correlation tests were used for analysis. 
P‑values less than 0.05 were considered significant.
RESULTS
Fifty‑three eyes of 51 patients including 7 female and 
44 male subjects with mean age of 45.01 ± 8.9 years 
were studied. The mean duration of symptoms was 
12.6 ± 18.01 months. The subjects were followed for a 
mean period of 19.51 ± 14.04 (range, 3‑60) months. All 
eyes had OCT imaging examinations at 3‑month intervals. 
Clinical examination and OCT images were available in 
27 eyes at 6 months and 23 eyes at 12 months of follow up.
Submacular fluid was present in all eyes at baseline 
examination. In 3 eyes (5.6%), subretinal fluid did 
not involve the foveal center and PED was present in 
11 eyes (20.7%). Subretinal fluid resolved in 51 eyes 
(96.2%), 12 months after half‑dose PDT. In 2 eyes (one 
patient), subretinal fluid decreased at the 3‑month visit; 
however, it did not resolve completely and an increase 
in subretinal fluid was detected on OCT examination 
one year after PDT. Subretinal fluid completely resolved 
after additional PDT in this patient. One patient with 
recurrence of subretinal fluid after complete resorption 
of fluid (14 months after PDT) refused additional 
treatment. Mean baseline central subfield thickness 
was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 
247 ± 49.7, and 244 ± 49.52 μm three, six and twelve 
months after PDT respectively (all P‑values < 0.001).
Mean BCVA was 0.33 ± 0.27 LogMAR before PDT 
which was significantly improved to 0.11 ± 0.18, 
0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR three, 
six and twelve months after PDT, and at the last visit, 
respectively (all P‑values < 0.001). Range of BCVA was 
20/20 to 20/200 before and 20/16 to 20/200, 20/20 to 
20/100, 20/16 to 20/200, and 20/20 to 20/200 at months 
3, 6 and 12, and at the last visit after PDT, respectively. At 
last follow up, BCVA was improved in 46 eyes (86.7%). 
An increase of ≥2 lines in BCVA occurred in 20 eyes 
(37.7%). No eye showed a decrease in BCVA.
No significant correlation was found between 
improvements in BCVA, and patient age and duration of 
symptoms (P = 0.6 and P = 0.8, respectively). Statistically 
significant correlations were observed between 
improvements in BCVA and baseline BCVA, baseline 
central subfield thickness and central subfield thickness 
after absorption of subretinal fluid (P < 0.001, P = 0.04, 
and P = 0.01, respectively). More BCVA improvement 
was found in eyes with worse baseline BCVA, higher 
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baseline central subfield thickness and lower post‑PDT 
central subfield thickness.
No complications attributed to PDT such as RPE tear 
or choroidal neovascularization were observed during 
the follow‑up period.
DISCUSSION
The exact cause of CSC remains unclear; however, it 
is believed that abnormal choroidal vessels play a key 
role in the pathogenesis of CSC.[1] Increased choroidal 
hyperpermeability as shown by ICGA suggests that 
treatment targeted to the choroidal vasculature might 
be useful in eliminating the cause of the disease.[1] PDT 
induces transient occlusion of abnormal choroidal vessels 
and alters choroidal permeability.[13] Previous studies 
have shown beneficial anatomical and visual outcomes 
with verteporfin PDT for treatment of chronic or 
recurrent CSC.[1‑12] In the largest reported study, members 
of the Macula Society were surveyed to collect data on 
PDT treatment for CSC.[14] A total of 265 eyes were treated 
with normal or half‑fluence PDT and subretinal fluid 
resolved in 81%. Complications were reported in 5.5% 
including RPE atrophy in 4% and acute severe decrease 
in vision in 1.5% of patients.
Considering the complications of standard PDT, and 
regarding the good baseline and potential for visual 
acuity recovery in CSC patients, modifications in PDT 
parameters have been suggested. Reduction of the 
laser radiation dose to half (half‑fluence modification) 
is more popular than reducing the dose of verteporfin 
(half‑dose PDT).[14] Single‑session half‑fluence PDT 
(25 J/cm2) has been reported to result in complete 
resolution of subretinal fluid in 84‑100% of subjects 
with a recurrence rate of 0‑29% in chronic CSC.[1,8,15,16] 
Corresponding figures after half‑dose PDT are 89.2‑100% 
and 0‑17.2%.[1,4,8,11] Three authors directly compared the 
results of half‑dose and half‑fluence PDT in chronic CSC. 
Alkin et al[7]compared 36 eyes after low‑fluence PDT 
and 28 eyes after half‑dose verteporfin PDT. Complete 
resolution of subretinal fluid was found in 91.6% and 
92.8% of cases in the low‑fluence and half‑dose PDT 
groups, respectively. Nicoló et al[8] reported more 
rapid absorption of fluid and a more lasting effect with 
half‑dose PDT relative to half‑fluence PDT. They found 
complete resolution of subretinal fluid in 26 half‑fluence 
treated eyes (83.9%) and 29 half‑dose treated eyes 
(100%) at 12 months. Recurrence rate was 29% in the 
half‑fluence group and 17.2% in the half‑dose group. 
In contrast to the mentioned reports suggesting better 
results with half‑dose PDT, Kim et al[12] reported no 
significant differences in visual or anatomical outcomes 
of 52 patients after either low‑fluence or half‑dose 
PDT (26 patients per group). They reported complete 
photoreceptor recovery at 12 months in 19 (73%) and 
14 patients (54%) in the half‑fluence and half‑dose 
groups, respectively (P = 0.150).
Fujita et al[11] reported the largest series of patients 
with chronic CSC treated with half‑dose PDT. They 
reported that 12 months after PDT, 89.2% of 204 eyes 
(of 204 patients) had complete resolution of serous 
detachment. Eleven eyes (5.4%) had persistent subretinal 
fluid throughout the follow‑up period and the recurrence 
rate was 5.9%. In the present study, we found complete 
resolution of subretinal fluid in 96.2% of eyes 12 months 
after half‑dose PDT. With additional PDT and at final 
examination, 98.1% of eyes had complete resolution of 
subretinal fluid. We found an improvement of BCVA in 
46 (86.7%) eyes and an increase of ≥2 lines in BCVA in 
20 (37.7%) eyes; this is similar to the findings of previous 
studies reporting an improvement of one line in 50‑84% 
and at least 2 lines in 26‑59% of eyes after PDT.[7,9,14] As 
evident, a discrepancy exists between the rate of fluid 
resolution and VA improvement which has also been 
described in other studies.[14,17] Lim et al[14] proposed 
that this discrepancy may be explained by irreversible 
damage to photoreceptors or the underlying RPE, or 
both due to chronicity of subretinal fluid.
Small sample size, retrospective design, and absence 
of a control group are major limitations of our study. 
Furthermore, we did not report the correlation between 
visual acuity and integrity of retinal layers. Despite 
these limitations, this is one of the largest series 
reporting promising outcomes with half‑dose PDT 
in patients with chronic CSC. Although resolution of 
subretinal fluid was observed in the majority of patients, 
significant improvement in visual acuity may not occur 
in all eyes.
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